← Retour à la une
Asie · Marchés régionaux · Pulse (Maeil Business)

Lotte chief calls biotech a key growth engine for group’s future

Publié par Pulse (Maeil Business) · Corée du Sud il y a 1 j
Lotte Biologics’ Songdo Bio Campus in Incheon. (Lotte Biologics)
Lotte Biologics’ Songdo Bio Campus in Incheon. (Lotte Biologics) · Pulse (Maeil Business)

Résumé détaillé

Lotte Group Chairman Shin Dong-bin has underscored the importance of the biotechnology industry as a key future growth driver for the conglomerate, pledging to help strengthen…

Lotte Group Chairman Shin Dong-bin has underscored the importance of the biotechnology industry as a key future growth driver for the conglomerate, pledging to help strengthen South Korea’s industrial competitiveness.

“The biotech industry is a future growth engine for Lotte Group and a next-generation industry that will lead Korea’s future,” Shin said Wednesday at a completion ceremony for the first plant at Lotte Biologics’ Bio Campus in Songdo, Incheon.

With the completion of the first plant, Lotte Biologics has secured a domestic production base with an annual capacity of 120,000 liters, in addition to its Syracuse facility in the United States.

The new facility is expected to accelerate Lotte Group’s global contract development and manufacturing organization (CDMO) business, one of its key future growth areas.

“I hope the first plant at the Songdo Bio Campus will serve as an important turning point in strengthening the competitiveness of Korea’s biotech industry, beyond contributing to Lotte Group’s growth,” Shin said. “We will create jobs centered around Songdo and nurture specialized talent in the biotech sector.”

About 300 people attended the ceremony, including Shin, Lotte Biologics co-CEOs James Park and Shin Yoo-yeol, and Incheon Mayor Park Chan-dae.

Shin Yoo-yeol, who made his first official public appearance since being promoted to Lotte Group president on Tuesday, said the company would seek to become a long-term CDMO partner to its customers.

He said that the conglomerate will “build lasting partnerships with customers based on quality, technology and trust that they can experience firsthand.”

Construction of the first plant began in March 2024, and the facility received approval for use in June this year. Spanning approximately 99,559 square meters, the site includes a production building for biopharmaceuticals, a utility building supplying water and electricity for operations, and a wastewater treatment facility.

Début de l'article, extrait de Pulse (Maeil Business). Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Pulse (Maeil Business) Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (pulse.mk.co.kr)

À lire aussi